<ul>
<li>HUTCHMED flagged pivotal Phase II results for fanregratinib in FGFR2-altered intrahepatic cholangiocarcinoma, scheduled for presentation July 4, 2026.     *      The study showed meaningful tumor shrinkage in a heavily pretreated population, with rapid onset and sustained disease control.     *      China’s drug regulator accepted the NDA in December 2025, granting priority review for previously treated advanced, metastatic, or unresectable disease.     *      Safety was broadly consistent with selective FGFR inhibitors, with limited treatment discontinuations and no treatment-related deaths reported. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606242000PRIMZONEFULLFEED9751900) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

00013

<p>HUTCHMED announced Phase II results for fanregratinib in FGFR2-altered intrahepatic cholangiocarcinoma, showing a 42.5% response rate with rapid onset and sustained disease control. The China NMPA accepted the NDA in December 2025, granting priority review. Safety profiles were consistent with selective FGFR inhibitors, with no treatment-related deaths reported.</p>

HUTCHMED says Phase II fanregratinib trial in FGFR2-altered bile duct cancer posts 42.5% response rate